ROC

(2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide

ROC is found in 25 entries

ROC as free ligands, exist in 25 entries. Examples include 1C6Z, 1FB7, 1HXB

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Name (2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide
Identifiers N~1~-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinolin-2-ylcarbonyl)-L-aspartamide
Synonyms Fortovase
SAQUINAVIR,RO 31-8959
Formula C38 H50 N6 O5
Molecular Weight 670.84 g/mol
Type peptide-like
Isomeric SMILES CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
InChI InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
InChI Key QWAXKHKRTORLEM-UGJKXSETSA-N
Subcomponents QNC ASN HP0 NTB

Chemical Details

Formal Charge 0
Atom Count 99
Chiral Atom Count 6
Chiral Atoms CA C9 CA1 C21 C3A C7A
Bond Count 103
Aromatic Bond Count 17

Drug Info: DrugBank

DrugBank ID DB01232   (Different stereochemistry)
Name Saquinavir
Groups
  • approved
  • investigational
Description An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem]
Synonyms
  • Saquinavir Mesylate
  • SQV
Brand Names
  • Fortovase Roche
  • Invirase
  • Invirase - Cap 200mg
  • Fortovase
  • ROC
Affected Organism Human Immunodeficiency Virus
Indication For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
Pharmacology Saquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of action Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Route of administration oral
Categories
  • HIV Protease Inhibitors
  • ["D27.505.519.389.745.420", "D27.505.954.122.388.077.088.420"]
  • P-glycoprotein/ABCB1 Inhibitors
  • []
  • P-glycoprotein/ABCB1 Substrates
  • []
[more]
ATC-Code J05AE01
AHFS-Code 08:18.08.08
CAS number 127779-20-8

Drug Targets

Name Sequence Search Pharmacological Action Actions
HIV-1 Protease Search yes inhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682